Kyntheum® is a fully human monoclonal antibody and the only biologic treatment
for moderate to severe plaque psoriasis that selectively targets the IL-17 receptor subunit A2,3
This means that it blocks multiple IL-17 cytokines with an active role in the pathogenesis of plaque psoriasis2,3
COMPLETE CLEARANCE WITH KYNTHEUM®
INDUCTION WAS SUSTAINED
THROUGH TO ONE YEAR.1
For illustrative purposes only. These images provide a look at Kyntheum® impact on one particular patient in the AMAGINE-1 study and do not necessarily represent the results experienced by all patients.
WITH KYNTHEUM® (210mg Q2W),
51% OF PATIENTS ACHIEVED PASI 100
AT 1 YEAR COMPARED TO 28%
PASI 100 responses during induction and maintenance (pooled AMAGINE-2 and AMAGINE-3).1
*Psoriasis Area Severity index
** Data are combined from AMAGINE-2 and AMAGINE-3
ꝉ Every two weeks
Kyntheum® is delivered in pre-filled syringes each containing 210 mg of brodalumab in 1.5 ml solution.
1 ml of solution contains 140 mg of brodalumab.1
List of excipients:
Water for injections
Solution for injection.
The solution is clear to slightly opalescent, colourless to slightly yellow and free of particles1.
Kyntheum® blocks the biological activity of the proinflammatory cytokines IL-17A, IL-17F, heterodimer IL-17A/F and IL-17E,
and inhibits inflammation and the clinical symptoms associated with psoriasis1.
Special Precautions for Storage
Store in the refrigerator (2° to 8° C).
Do not freeze.
Keep the pre-filled syringe in the outer box to protect it from light1.
Kyntheum® may be stored at room temperature (up to 25°C) once, in the outer carton, for a maximum single period of 14 days.
Once Kyntheum® has been removed from the refrigerator and has reached room temperature (up to 25°C)
it must either be used within 14 days or discarded1.